Navigation Links
GSK Does Not Option XL784 for Further Development
Date:1/18/2008

/p>

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy of Exelixis' compounds, including the other compounds on which GSK has an option, and the likelihood that GSK will exercise its option to license additional compounds for further development and commercialization. Words such as "believes," "intend," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of Exelixis' compounds to demonstrate safety and efficacy in clinical testing and Exelixis' dependence on and relationship with GSK. These and other risk factors are discussed under "Risk Factors" and elsewhe
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
2. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
3. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
4. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
9. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. St. Jude Defines Eye Cancer Genes Role in Retinal Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... 2011 As NFL coaches and players face a dramatically ... team,s preparation will be gaining a competitive edge as it ... Today, Polar USA and the Atlanta Falcons announced that the ... Heart Rate Training System" of the Atlanta Falcons. ...
... CINCINNATI, Sept. 7, 2011 HealthWarehouse.com, Inc. (OTC: HEWA) ... that Lalit Dhadphale, president and CEO of HealthWarehouse.com, will ...  The presentation will begin at 10:00 a.m. Eastern Time ... invited to listen to a live web cast of ...
Cached Medicine Technology:Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 3
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... Pharmaceutical Marketing Industry Due to New PhRMA Marketing ... Pharmaceutical marketers are taking on the 2009 ... a unique marketing company whose integrated engagement solutions ... sector. In the past two years the company ...
... Disease Depend on Plasma DonationANNAPOLIS, Md., Jan. 6 Kawasaki ... between the ages of two and five and is ... in the United States according to the American Heart ... globulin (IVIG), a plasma-derived therapy that replaces vital missing ...
... flow leader positioned for expanding role of patient flow ... has been helping its clients, now more than 700 ... The need to increase capacity and improve patient ... of U.S. hospitals have postponed building and expansion plans ...
... Music Organization Will Offer "The Prevention Plan(TM)" Health ... Preventive Medicine(R), the leader in disease prevention, today ... performing right organization that represents more than 375,000 ... Prevention Plan(TM) to its members at a discount. ...
... N.C., Jan. 6 Compass Group North America ... of Harwood Heights,Illinois-based KIMCO Corporation, a provider of ... sector. Through the acquisition, KIMCO,becomes a wholly owned ... a division of Compass Group North America focused ...
... Rising Medical Solutions, Inc. (Rising), a,leading medical ... Company will provide Medical Data Call services for ... data to the National Council on,Compensation Insurance, Inc. ... http://www.newscom.com/cgi-bin/prnh/20080206/AQW030LOGO-b ) , ...
Cached Medicine News:Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 2Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 3Health News:Kawasaki Disease Treated with Plasma-Derived Therapy 2Health News:TeleTracking Technologies to Focus on Growth 2Health News:TeleTracking Technologies to Focus on Growth 3Health News:U.S. Preventive Medicine(R) Strikes a Note with Broadcast Music, Inc. 2Health News:Compass Group North America Acquires KIMCO Corporation 2Health News:Rising Medical Solutions to Provide NCCI Medical Data Call Services 2
... one of our highly featured models. This model has ... target using the mouse to have the patient look ... allow the unit to photograph a particular area on ... after you have taken the picture you can ascertain ...
... laser combines excellent cutting, ablation and ... procedures. It is also extremely effective ... stones of all compositions, making it ... its laser light is transmitted through ...
... Thanks to the progress and perfecting ... techniques have acquired a more strategic role ... technology in this sector has certainly contributed ... various urological pathologies that are becoming more ...
... PhotoLightFACIAL facial skin treatment, vascular ... Incorporates a wide range ... multiple hand pieces and large ... the most flexibility. Compact ...
Medicine Products: